# A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain

> **NCT00662558** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 802 (actual)

## Conditions studied

- Low Back Pain

## Interventions

- **DRUG:** celecoxib
- **DRUG:** tramadol HCL

## Key facts

- **NCT ID:** NCT00662558
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 802 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662558, "A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00662558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*